CAREDX, INC. (NASDAQ:CDNA) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing


CAREDX, INC. (NASDAQ:CDNA) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item3.01. Notice of Delisting or Failure to Satisfy a Continued
Listing Rule or Standard; Transfer of Listing.

On April19, 2017, CareDx, Inc. (the Company) received a written
notice (the Notice) from the Listing Qualifications Department of
The NASDAQ Stock Market LLC (Nasdaq) stating that the Company is
not in compliance with Nasdaq Listing Rule 5250(c)(1) for
continued listing because the Company did not timely file with
the U.S. Securities and Exchange Commission (the SEC) its Annual
Report on Form 10-K for the year ended December31, 2016 (the Form
10-K). The Notice was issued in accordance with standard Nasdaq
procedures and has no immediate effect on the continued listing
of the Companys common stock on the Nasdaq Global Market.

The Notice indicates that the Company has until June19, 2017 to
submit a plan to regain compliance with the Nasdaq continued
listing standards. The Company filed the Form 10-K with the SEC
on April21, 2017 and has regained compliance with Nasdaq Listing
Rule 5250(c)(1).

Item7.01. Financial Statements and Exhibits.

On April21, 2017, the Company issued a press release disclosing
the Companys receipt of the Notice. A copy of the press release
is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Item7.01, including Exhibit
99.1 hereto, is being furnished and shall not be deemed filed for
the purposes of Section18 of the Securities Exchange Act of 1934,
as amended (the Exchange Act), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference into any registration statement or other filing
under the Securities Act of 1933, as amended, or the Exchange
Act, except as shall be expressly set forth by specific reference
to such filing.

Cautionary Note Regarding Forward-Looking Statements.
This Current Report on Form 8-K and the press release furnished
as Exhibit 99.1 hereto contain forward-looking statements which
involve certain risks and uncertainties that could cause actual
results to differ materially from those expressed or implied by
these statements. Please refer to the note in the press release
under the heading Forward-Looking Statements regarding these
forward-looking statements.

Item9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is being furnished herewith:



99.1 Press Release, dated April 21, 2017.


CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.

CAREDX, INC. (NASDAQ:CDNA) Recent Trading Information

CAREDX, INC. (NASDAQ:CDNA) closed its last trading session up +0.05 at 1.00 with 103,032 shares trading hands.

An ad to help with our costs